JCIA
TBPH

Jackson Creek Investment Advisors’s Theravance Biopharma TBPH Stock Holding History

Jackson Creek Investment Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Sell
85,508
-33,052
-28% -$547K 0.48% 73
2026
Q1 		$1.92M Buy
+118,560
New +$2.1M 0.57% 39

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jackson Creek Investment Advisors's TBPH Position: Q2 2026 in Review

Jackson Creek Investment Advisors reduced its Theravance Biopharma (TBPH) stake by 28% in Q2 2026, selling an estimated $547K and leaving 85,508 shares worth $1.44M. The position accounts for 0.48% of the portfolio, ranked #73.

Jackson Creek Investment Advisors first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.92M in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Jackson Creek Investment Advisors held 85,508 shares of Theravance Biopharma worth $1.44M as of Q2 2026.
  • Jackson Creek Investment Advisors sold 33,052 Theravance Biopharma shares in Q2 2026, an estimated $547K.
  • Theravance Biopharma made up 0.48% of Jackson Creek Investment Advisors's portfolio in Q2 2026, its #73 holding.
  • Jackson Creek Investment Advisors first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • Jackson Creek Investment Advisors's Theravance Biopharma position peaked at $1.92M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.